Contact Information

37 Westminster Buildings, Theatre Square,
Nottingham, NG1 6LG

We Are Available 24/ 7. Call Now.

Epigral Ltd aims to grow at an annual rate of 20 per cent and is poised to more than double its revenue by FY28, a top company official said on Saturday.

Sustained demand for derivative and speciality products as well as doubling of production capacity will act as key catalysts for the overall revenue growth, Epigral’s Chairman and Managing Director, Maulik Patel said in a statement.

The company’s consolidated revenue for 2023-24 stood at ₹1,936 crore.

Epigral reported a little over 37 per cent jump in consolidated revenue to ₹1,934.31 crore in the first nine months of 2024-25 compared to ₹1,409.55 crore in the year-ago period, according to exchange filings.

  • Also read: Broker’s call: Epigral (Buy)

Derivatives and speciality business contributed 54 per cent to the topline.

As per a research report by Sunidhi, Epigral’s revenue is expected to be over 3,500 crore by FY27. Another research firm Emkay in its report states that it expects revenue to be ₹3,800 crore by FY27 with an EBITDA margin of 26 per cent.

The company is doubling its capacity of Chlorinated Polyvinyl Chloride (CPVC) from 75,000 metric tons per annum to 1,50,000 MTPA and Epichlorohydrin capacity from 50,000 MTPA to 1,00,000 MTPA at its existing complex in Dahej with an investment close to ₹780 crore.

With this new capex, captive chlorine consumption will improve and facilitate higher contribution from derivatives and speciality products. CPVC is one of the key ingredients in plumbing systems.

“We expect our volumes to be driven from the diversified projects that we will be commissioning in the coming 3 to 5 years, thereby creating value for our stakeholders.” Patel said.

  • Also read: India’s plastic pipe industry has significant headroom for growth: Jefferies

“We focus on low-cost operations on account of fully backward and forward integration and continuous addition of value-added products. Our investment in setting up a research and development centre will further strengthen our presence in speciality chemicals and adding molecules in Chlorotoluenes value chain,” he added.

For the third quarter of FY25, the company reported more than a two-fold jump in net profit to ₹103.63 crore compared to ₹49 crore in the year-ago period.

Revenue rose to ₹649 crore in the December quarter from ₹474 crore in the year-ago period.



Source link


administrator

Leave a Reply

Your email address will not be published. Required fields are marked *